458 related articles for article (PubMed ID: 24894776)
1. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.
Braun DL; Rauch A; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Metzner KJ; Böni J; Weber R; Fehr J
HIV Med; 2014 Nov; 15(10):625-30. PubMed ID: 24894776
[TBL] [Abstract][Full Text] [Related]
2. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
[TBL] [Abstract][Full Text] [Related]
3. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
[TBL] [Abstract][Full Text] [Related]
4. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F;
J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903
[TBL] [Abstract][Full Text] [Related]
5. Optimizing treatment in HIV/HCV coinfection.
Puoti M; Rossotti R; Travi G; Panzeri C; Morreale M; Chiari E; Cocca G; Orso M; Moioli MC
Dig Liver Dis; 2013 Sep; 45 Suppl 5():S355-62. PubMed ID: 24091116
[TBL] [Abstract][Full Text] [Related]
6. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy.
Labarga P; Fernandez-Montero JV; Barreiro P; Pinilla J; Vispo E; de Mendoza C; Plaza Z; Soriano V
J Viral Hepat; 2014 Jul; 21(7):475-9. PubMed ID: 24750394
[TBL] [Abstract][Full Text] [Related]
7. High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy.
Biermer M; Schlosser B; Fülöp B; van Bömmel F; Brodzinski A; Heyne R; Keller K; Sarrazin C; Berg T
J Viral Hepat; 2012 Aug; 19(8):547-53. PubMed ID: 22762138
[TBL] [Abstract][Full Text] [Related]
8. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection.
Martel-Laferrière V; Brinkley S; Bichoupan K; Posner S; Stivala A; Perumalswami P; Schiano T; Sulkowski M; Dieterich D; Branch A
HIV Med; 2014 Feb; 15(2):108-15. PubMed ID: 24025147
[TBL] [Abstract][Full Text] [Related]
9. Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme.
Gori A; Doroana M; Chernova O; Rockstroh JK; Banhegyi D; Bergin C; Verucchi G; Liu C; DeMasi R; Hadacek B; Nelson M
J Infect; 2015 Dec; 71(6):675-82. PubMed ID: 26416471
[TBL] [Abstract][Full Text] [Related]
10. Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.
Hasson H; Messina E; Merli M; Della Torre L; Morsica G; Bagaglio S; Lazzarin A; Uberti-Foppa C
Int J Infect Dis; 2014 Dec; 29():100-2. PubMed ID: 25449243
[TBL] [Abstract][Full Text] [Related]
11. Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfected patients: possible role of the hepatitis C virus sustained viral response.
Bani-Sadr F; Loko MA; Pambrun E; Winnock M; Carrieri P; Gilbert C; Duvivier C; Bouchaud O; Gervais A; Dabis F; Salmon D;
AIDS; 2014 May; 28(8):1155-60. PubMed ID: 24499953
[TBL] [Abstract][Full Text] [Related]
12. Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies.
Labarga P; Fernández-Montero JV; López M; Barreiro P; de Mendoza C; Sierra-Enguita R; Treviño A; Soriano V
Antivir Ther; 2014; 19(8):799-803. PubMed ID: 24964405
[TBL] [Abstract][Full Text] [Related]
13. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
[TBL] [Abstract][Full Text] [Related]
14. Hepatic histologic response (HR) to combination therapy among HCV/HIV-coinfected individuals: interferon induces HR independent of sustained virologic response (SVR).
Wu L; Kottilil S; Lempicki R; Yang J; McLaughlin M; Hu Z; Koratich C; Reitano KN; Rehm CA; Masur H; Wood B; Kleiner DE; Polis MA
AIDS Res Hum Retroviruses; 2006 Nov; 22(11):1091-8. PubMed ID: 17147494
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.
Hara T; Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Kumada H
J Med Virol; 2013 Oct; 85(10):1746-53. PubMed ID: 23861088
[TBL] [Abstract][Full Text] [Related]
16. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.
Loko MA; Bani-Sadr F; Winnock M; Lacombe K; Carrieri P; Neau D; Morlat P; Serfaty L; Dabis F; Salmon D;
J Viral Hepat; 2011 Jul; 18(7):e307-14. PubMed ID: 21692942
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects.
Genebat M; Vera F; Hernández-Quero J; Domingo P; Guardiola JM; Martínez-Madrid O; Martínez L; de la Llana FG; Sánchez-Villegas J; Alvarez H; Mariño A; Lluch JF; Martínez-Pérez MA; Marín J; Ruiz-Mateos E; Leal M
Antiviral Res; 2014 Apr; 104():59-61. PubMed ID: 24491797
[TBL] [Abstract][Full Text] [Related]
18. Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient.
Payer BA; Reiberger T; Rutter K; Beinhardt S; Staettermayer AF; Peck-Radosavljevic M; Ferenci P
J Clin Virol; 2010 Oct; 49(2):131-3. PubMed ID: 20709593
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
20. Management of hepatitis C virus coinfection in HIV-infected persons.
O'Leary JG; Chung RT
AIDS Read; 2006 Jun; 16(6):313-6, 318-20. PubMed ID: 16795921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
